Kusajili – Clinical trials directory

Result of your search per sponsor: Beaufour Ipsen Pharma-Ipsen Biotech Department

Woman and Man Max 99 years
Beaufour Ipsen Pharma-Ipsen Biotech Department Update Il y a 4 ans

Phase III multicentre, Randomised, Double Blind, Comparative study to assess the efficacy and safety of lanreotide 30mg versus placebo as a palliative treatment of clinical symptoms associated with intestinal obstruction due to peritoneal carcinomatosis in inoperable patients The primary objective of this study is to assess the efficacy of lanreotide 30 mg as compared to placebo to relieve clinical symptoms due to small bowel obstruction in inoperable patients with periton...

Country None
organs None
Specialty None

Closed trial

More information